

Malignant Ascites Market Poised for Robust Growth by 2034, Says DelveInsight

DelveInsight's Malignant Ascites Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

LAS VEGAS , NV, UNITED STATES, January 21, 2025 /EINPresswire.com/ -- DelveInsight's "Malignant Ascites Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the Malignant Ascites, historical and forecasted epidemiology as well as the Malignant Ascites market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

To Know in detail about the Malignant Ascites market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: [Malignant Ascites Market Forecast](#)

Some of the key facts of the Malignant Ascites Market Report:

- The Malignant Ascites market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
- In January 2025, BeiGene's PD-1 inhibitor Tevimbra (tislelizumab-jsgr) was approved by the US Food and Drug Administration (FDA) as part of a first-line combination treatment for advanced gastric cancer.
- In December 2024, EndoQuest Robotics gained FDA IDE approval for a clinical trial to evaluate its surgical robot in colorectal lesion removal. The trial, focusing on the safety and performance of the system in ESD procedures, will involve 50 participants across five US sites (NCT06133387).
- In December 2024, Verastem Oncology announced the FDA's acceptance of its New Drug Application (NDA) for avutometinib, a RAF/MEK clamp, combined with defactinib, a FAK inhibitor, under the accelerated approval pathway for treating KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) in adults after prior systemic therapy.
- In September 2024, Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the FDA approval of KEYTRUDA, Merck's anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
- Among the 7MM, the United States accounted for the highest incident cases of Malignant Ascites in 2020, with around 350,000 cases, a number expected to rise during the forecast period.

- Among all the associated cancers, Breast Cancer had the highest incident cases, with 640,000 reported in 2020.
- In 2020, the total patient pool of Malignant Ascites in the EU4 and the UK was around 390,000.
- The Malignant Ascites market is expected to reach approximately USD 2,340 Million by 2034, reflecting a significant growth trajectory.
- Emerging therapies for Malignant Ascites include CATUMAXOMAB, M 701, SCB-313, VAK, CYPSCAPS PLUS IFOSFAMIDE, and others.
- Key companies in the Malignant Ascites space include Lindis Biotech, Wuhan Yzy Biopharma Co., Ltd., Clover Biopharmaceuticals, Binhui Biopharmaceutical, Pharmacyte Biotech Inc., and others.
- The Malignant Ascites market is set for substantial growth due to increasing cases, rising demand for effective therapies, and advancements in treatment options aimed at improving patient outcomes.

Malignant Ascites Overview

Malignant ascites (MA) is a pathological condition associated with various primary abdominal and extra-abdominal tumors. It is a significant cause of morbidity and poses numerous treatment challenges. MA indicates peritoneal carcinomatosis, characterized by the presence of malignant cells in the peritoneal cavity. The tumors responsible for carcinomatosis are often secondary peritoneal surface malignancies, including ovarian, colorectal, pancreatic, and uterine cancers. Additionally, it may result from extra-abdominal tumors such as lymphoma, lung, and breast cancers, as well as a small percentage of

Get a Free sample for the Malignant Ascites Market Report:

https://www.delveinsight.com/report-store/malignant-ascites-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=jpr

Malignant Ascites Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Malignant Ascites Epidemiology Segmentation:

The Malignant Ascites market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

- Incident Cases of Malignant Ascites in Selected Indications in the 7MM
- Total Incident Cases of Ascites in Selected Indications (Ovarian, Colorectal, Gastric ,and Others) in the 7MM
- Total Treated Cases of Malignant Ascites in the 7MM

Download the report to understand which factors are driving Malignant Ascites epidemiology

trends @ [Malignant Ascites Epidemiology Forecast](#)

Malignant Ascites Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Malignant Ascites market or expected to be launched during the study period. The analysis covers Malignant Ascites market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Malignant Ascites Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Malignant Ascites Therapies and Key Companies

- CATUMAXOMAB: LINDIS BIOTECH
- M 701: WUHAN YZY BIOPHARMA CO., LTD.
- SCB-313: CLOVER BIOPHARMACEUTICALS
- VAK: BINHUI BIOPHARMACEUTICAL
- CYPSCAPS PLUS IFOSFAMIDE: PHARMACYTE BIOTECH INC.

Malignant Ascites Market Strengths

- The increasing prevalence of cancers such as breast, ovarian, and gastric cancer, which are commonly associated with Malignant Ascites, creates a larger patient pool and drives the demand for treatment options.
- The development of new therapies and innovative treatment options for Malignant Ascites, including monoclonal antibodies and combination therapies, is enhancing treatment efficacy and improving patient outcomes.

Malignant Ascites Market Opportunities

- With promising therapies such as CATUMAXOMAB, M 701, and SCB-313 in development, there is significant potential for new and more effective treatments, creating opportunities for market growth and improved patient care.
- As awareness of Malignant Ascites grows, early diagnosis and treatment are becoming a priority. This trend presents opportunities for innovations in diagnostic tools and therapeutics tailored to the early stages of the disease.

Scope of the Malignant Ascites Market Report

- Study Period: 2020–2034
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Malignant Ascites Companies: Lindis Biotech, Wuhan Yzy Biopharma Co., Ltd., Clover

Biopharmaceuticals, Binhui Biopharmaceutical, Pharmacyte Biotech Inc., and others.

- Key Malignant Ascites Therapies: CATUMAXOMAB, M 701, SCB-313, VAK, CYPSCAPS PLUS IFOSFAMIDE, and others.
- Malignant Ascites Therapeutic Assessment: Malignant Ascites current marketed and Malignant Ascites emerging therapies
- Malignant Ascites Market Dynamics: Malignant Ascites market drivers and Malignant Ascites market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Malignant Ascites Unmet Needs, KOL's views, Analyst's views, Malignant Ascites Market Access and Reimbursement

To learn more about Malignant Ascites companies working in the treatment market, visit @ [Malignant Ascites Clinical Trials and Therapeutic Assessment](#)

Table of Contents

1. Malignant Ascites Market Report Introduction
2. Executive Summary for Malignant Ascites
3. SWOT analysis of Malignant Ascites
4. Malignant Ascites Patient Share (%) Overview at a Glance
5. Malignant Ascites Market Overview at a Glance
6. Malignant Ascites Disease Background and Overview
7. Malignant Ascites Epidemiology and Patient Population
8. Country-Specific Patient Population of Malignant Ascites
9. Malignant Ascites Current Treatment and Medical Practices
10. Malignant Ascites Unmet Needs
11. Malignant Ascites Emerging Therapies
12. Malignant Ascites Market Outlook
13. Country-Wise Malignant Ascites Market Analysis (2020–2034)
14. Malignant Ascites Market Access and Reimbursement of Therapies
15. Malignant Ascites Market Drivers
16. Malignant Ascites Market Barriers
17. Malignant Ascites Appendix
18. Malignant Ascites Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Jatin Vimal

DelveInsight Business Research LLP

+1 469-945-7679

info@delveinsight.com

This press release can be viewed online at: <https://www.einpresswire.com/article/778909590>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.